Circulating microRNAs as Early Biomarkers of Breast Cancer: A Nested Case-Control Study Within a Prospective Cohort in Italy
Authors:
- Lisa PadroniLPLisa Padroni
- Giorgia MarmiroliGMGiorgia Marmiroli
- Laura De MarcoLMLaura De Marco
- Valentina FianoVFValentina Fiano
- Saverio CainiSaverio Caini
- Claudia AgnoliCAClaudia Agnoli
- Claudia VenerCVClaudia Vener
- Vittorio SimeonVSVittorio Simeon
- Salvatore PanicoSPSalvatore Panico
- Luca ManfrediLMLuca Manfredi
- Lorenzo MilaniLMLorenzo Milani
- Fulvio RicceriFulvio Ricceri
Open Access
- 16 March 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2706
Abstract
Circulating microRNAs (miRNAs) are promising minimally invasive biomarkers for cancer risk assessment, yet prospective evidence for breast cancer (BC) remains limited. We conducted a nested case–control study within a prospective cohort to examine whether pre-diagnostic circulating miRNAs are associated with subsequent BC risk and to explore their potential relevance in prospective population-based settings. Baseline serum from 160 women (80 incident BC cases; 80 matched controls) was analyzed, with a median time to diagnosis of 8.9 years. Eight candidate miRNAs were quantified by droplet digital PCR (ddPCR) and normalized to miR-484. Group differences were evaluated by non-parametric tests, and odds ratios for BC were estimated using logistic regression models adjusted for established risk factors, with Bonferroni correction for multiple testing. Cases and controls were comparable at baseline. Among the candidates, lower circulating miR-181 levels showed a suggestive inverse association with BC risk in fully adjusted models, while lower Let7 levels showed only a non-significant, hypothesis-generating inverse trend that did not survive Bonferroni correction. No other miRNA displayed clear associations with BC risk. These findings, while preliminary, support further large-scale prospective investigations specifically designed to assess predictive performance and external validation. employing standardized pre-analytical and analytical protocols, repeated sampling, and independent replication/external validation to clarify the etiologic relevance and potential risk-prediction value of circulating miRNAs for BC.Keywords
Funding Information
- Ministero della Salute (RF 2018 12366921)
This publication has 31 references indexed in Scilit:
- Expanding screening through the use of liquid biopsy for early cancer detectionCommunications Medicine, 2025
- Role of miRNAs in breast cancer development and progression: Current researchBioFactors, 2024
- MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advancesOncogene, 2024
- Plasma microRNA ratios associated with breast cancer detection in a nested case–control study from a mammography screening cohortScientific Reports, 2023
- MicroRNAs in the cancer cell-to-cell communication: An insight into biological vehiclesBiomedicine & Pharmacotherapy, 2022
- Competitive learning suggests circulating miRNA profiles for cancers decades prior to diagnosisRNA Biology, 2020
- Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patientsScientific Reports, 2018
- let-7 Regulates Self Renewal and Tumorigenicity of Breast Cancer CellsCell, 2007
- RAS Is Regulated by the let-7 MicroRNA FamilyCell, 2005
- MicroRNAs: small RNAs with a big role in gene regulationNature Reviews Genetics, 2004